Acute viral nasopharyngitis cost-effectiveness of therapy
|
Acute viral nasopharyngitis Microchapters |
|
Differentiating acute viral nasopharyngitis from other diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Acute viral nasopharyngitis cost-effectiveness of therapy On the Web |
|
American Roentgen Ray Society Images of Acute viral nasopharyngitis cost-effectiveness of therapy |
|
FDA on Acute viral nasopharyngitis cost-effectiveness of therapy |
|
CDC on Acute viral nasopharyngitis cost-effectiveness of therapy |
|
Acute viral nasopharyngitis cost-effectiveness of therapy in the news |
|
Blogs onAcute viral nasopharyngitis cost-effectiveness of therapy |
|
Risk calculators and risk factors for Acute viral nasopharyngitis cost-effectiveness of therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Cost-Effectiveness of Therapy
In the USA alone, the common cold leads to 75 to 100 million physician visits annually at a conservative cost estimate of $7.7 billion per year. Americans spend $2.9 billion on over-the-counter drugs and another $400 million on prescription medicines for symptomatic relief.[1][2]
More than one-third of patients who saw a doctor received an antibiotic prescription, which not only contributes to unnecessary costs ($1.1 billion annually on an estimated 41 million antibiotic prescriptions in the United States), but also has implications for antibiotic resistance from overuse of such drugs.[2]
An estimated 22 to 189 million school days are missed annually due to a cold. As a result, parents missed 126 million workdays to stay home to care for their children. When added to the 150 million workdays missed by employees suffering from a cold, the total economic impact of cold-related work loss exceeds $20 billion.[3][1][2]
References
- ↑ 1.0 1.1 Invalid
<ref>tag; no text was provided for refs namedpmid4014285 - ↑ 2.0 2.1 2.2 Fendrick AM, Monto AS, Nightengale B, Sarnes M (2003). "The economic burden of non-influenza-related viral respiratory tract infection in the United States". Arch. Intern. Med. 163 (4): 487–94. PMID 12588210.
- ↑ Invalid
<ref>tag; no text was provided for refs namedNIAID2006